Oppenheimer set a $8.00 target price on AzurRx BioPharma (NASDAQ:AZRX) in a report published on Tuesday, February 26th. The brokerage currently has a buy rating on the stock. Oppenheimer also issued estimates for AzurRx BioPharma’s FY2022 earnings at $0.11 EPS.
A number of other brokerages have also commented on AZRX. ValuEngine lowered AzurRx BioPharma from a buy rating to a hold rating in a research report on Wednesday, January 2nd. Roth Capital initiated coverage on AzurRx BioPharma in a research report on Friday, January 25th. They set a buy rating and a $10.50 price objective for the company. HC Wainwright set a $8.00 price objective on AzurRx BioPharma and gave the stock a buy rating in a research report on Friday, November 2nd. Finally, Maxim Group initiated coverage on AzurRx BioPharma in a research report on Thursday, February 14th. They set a buy rating and a $5.00 price objective for the company. One analyst has rated the stock with a hold rating and five have issued a buy rating to the company’s stock. The stock currently has a consensus rating of Buy and a consensus price target of $7.50.
AZRX traded up $0.01 during trading on Tuesday, reaching $2.27. The company had a trading volume of 47,005 shares, compared to its average volume of 104,741. AzurRx BioPharma has a 12-month low of $1.00 and a 12-month high of $3.75.
In related news, CEO Johan M. Spoor bought 38,583 shares of AzurRx BioPharma stock in a transaction that occurred on Friday, December 28th. The stock was purchased at an average cost of $1.30 per share, for a total transaction of $50,157.90. Following the acquisition, the chief executive officer now owns 338,617 shares in the company, valued at $440,202.10. The acquisition was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, major shareholder Edmund Burke Jr. Ross bought 66,122 shares of AzurRx BioPharma stock in a transaction that occurred on Thursday, December 27th. The stock was bought at an average price of $1.16 per share, with a total value of $76,701.52. The disclosure for this purchase can be found here. Over the last quarter, insiders have bought 186,553 shares of company stock valued at $231,349. 7.20% of the stock is owned by corporate insiders.
An institutional investor recently raised its position in AzurRx BioPharma stock. 683 Capital Management LLC increased its stake in AzurRx BioPharma Inc (NASDAQ:AZRX) by 73.9% in the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 695,504 shares of the company’s stock after purchasing an additional 295,504 shares during the quarter. 683 Capital Management LLC owned approximately 4.11% of AzurRx BioPharma worth $842,000 at the end of the most recent reporting period. 16.27% of the stock is owned by institutional investors.
AzurRx BioPharma Company Profile
AzurRx BioPharma, Inc researches and develops non-systemic biologics for the treatment of patients with gastrointestinal disorders. Its product pipeline consists of two therapeutic proteins under development, including MS1819, a yeast derived recombinant lipase, which is in Phase II clinical trial for the treatment of exocrine pancreatic insufficiency associated with chronic pancreatitis and cystic fibrosis; and AZX1101, an enzymatic combination of bacterial origin for the prevention of hospital-acquired infections and antibiotic-associated diarrhea.
See Also: Dividend Aristocrat Index
Receive News & Ratings for AzurRx BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AzurRx BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.